Filing Flows › Citius Pharmaceuticals (CTXR) › Q3 FY26 › vs Q2 FY26
Citius Pharmaceuticals (CTXR) Q3 FY26 vs Q2 FY26 (quarter over quarter)
Citius Pharmaceuticals's revenue fell $174K (-10%) from $1.7M in Q2 FY26 to $1.5M in Q3 FY26.
Citius Pharmaceuticals, Q3 FY26: revenue $1.5M, operating margin -785.4%, net loss $11.9M, operating cash flow −$8.7M. The chart draws each line against Q2 FY26, the increases inside each band.
Every line
| Line | Q3 FY26 | Q2 FY26 | Change | % |
|---|---|---|---|---|
| Revenue | $1.5M | $1.7M | −$174K | -10% |
| Income tax benefit | $107K | $231K | −$124K | -54% |
| Net loss | $11.9M | $28.1M | −$16.2M | -58% |
| Costs & expenses | $13.5M | $33.9M | −$20.3M | -60% |
| Operating costs | $13.2M | $33.9M | −$20.6M | -61% |
| Interest & other, net | $295K | −$3.9M | $4.1M | — |
| Cost of revenue | $492K | $329K | $163K | +50% |
| Research & development | $1.1M | $1.6M | −$580K | -35% |
| General & admin | $6.1M | $26.4M | −$20.2M | -77% |
| Other operating costs | $5.5M | $5.5M | $22K | +0.4% |
| Operating cash sources | $12.5M | $5.1M | $7.4M | +145% |
| Share-based compensation | $3.8M | $3.8M | $22K | +0.6% |
| Cash used in operations | $8.7M | $1.3M | $7.4M | +567% |
| Net loss absorbed | $11.9M | $28.1M | −$16.2M | -58% |
| Working capital & other | $569K | −$23.0M | $23.6M | — |
Questions
How much did Citius Pharmaceuticals's revenue grow quarter over quarter in Q3 FY26?
Citius Pharmaceuticals's revenue fell $174K (-10%) from $1.7M in Q2 FY26 to $1.5M in Q3 FY26.